Workflow
Immuneering (IMRX)
icon
Search documents
Immuneering (IMRX) - 2024 Q4 - Annual Results
2025-03-20 20:07
Financial Performance - Net loss attributable to common stockholders for Q4 2024 was $18.1 million, or $0.58 per share, compared to a net loss of $15.1 million, or $0.52 per share, in Q4 2023[10] - Full-year net loss attributable to common stockholders for 2024 was $61.0 million, or $2.04 per share, compared to $53.5 million, or $1.88 per share, for 2023[10] - Cash, cash equivalents, and marketable securities as of December 31, 2024, were $36.1 million, down from $85.7 million as of December 31, 2023[10] Research and Development - Reported an overall response rate (ORR) of 43% and a disease control rate (DCR) of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients[3] - Research and Development (R&D) expenses for Q4 2024 were $14.9 million, compared to $11.9 million in Q4 2023, with full-year R&D expenses of $48.0 million versus $41.6 million in 2023[10] - Initiation of multiple Phase 2a arms of IMM-1-104 in combination with various inhibitors planned for 2025[10] - FDA granted Fast Track designation for IMM-1-104 in advanced melanoma and Orphan Drug designation for pancreatic cancer[6][7] Management and Leadership - New Chief Medical Officer, Dr. Igor Matushansky, appointed to oversee clinical activities and development programs[4] Assets and Liabilities - Total assets decreased from $102,584,538 in December 31, 2023 to $52,714,413 in December 31, 2024, representing a decline of approximately 48.5%[20] - Current assets fell from $89,083,669 in December 31, 2023 to $39,587,569 in December 31, 2024, a decrease of about 55.6%[20] - Total liabilities reduced from $12,008,355 in December 31, 2023 to $11,328,187 in December 31, 2024, a decrease of about 5.7%[20] - Stockholders' equity decreased from $90,576,183 to $41,386,226, reflecting a decline of approximately 54.4%[20] - The accumulated deficit increased from $(163,258,578) to $(224,295,186), indicating a worsening of approximately 37.4%[20] Capital Structure - Additional paid-in capital rose from $253,806,267 to $265,650,362, an increase of about 4.7%[20] - Class A common stock shares issued increased from 29,271,629 to 31,050,448, representing a growth of about 6.1%[20] - Cash runway extended into 2026, supported by recent funding activities[9] - General and Administrative (G&A) expenses for Q4 2024 were $3.7 million, down from $4.4 million in Q4 2023, with full-year G&A expenses of $16.1 million compared to $16.8 million in 2023[10] - Total current liabilities slightly decreased from $7,845,503 to $7,503,768, a reduction of approximately 4.4%[20] - Lease liabilities, net of current portion decreased from $4,162,852 to $3,824,419, a decline of approximately 8.1%[20] - Cash and cash equivalents decreased significantly from $59,405,817 to $36,144,720, a drop of approximately 39.0%[20]
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Globenewswire· 2025-03-20 20:05
Core Insights - Immuneering Corporation reported positive data from its ongoing Phase 2a trial of IMM-1-104, showing an overall response rate (ORR) of 43% and a disease control rate (DCR) of 86% in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer [3][4] - The company has entered a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo for non-small cell lung cancer [4][8] - Cash runway has been extended into 2026, providing sufficient funding for ongoing operations [9] Clinical Developments - The Phase 2a trial of IMM-1-104 demonstrated promising results, with an ORR of 50% when combined with modified FOLFIRINOX, compared to historical benchmarks of 23% and 32% for the respective chemotherapy agents [3][4] - Plans are underway for a potential global pivotal trial of IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel [3][4] - Additional combination arms for IMM-1-104 are expected to be initiated in 2025, including studies with a BRAF inhibitor, a G12C inhibitor, and a PD-1 inhibitor [4][8] Financial Performance - As of December 31, 2024, the company reported cash and cash equivalents of $36.1 million, a decrease from $85.7 million as of December 31, 2023 [7][19] - Research and development (R&D) expenses for Q4 2024 were $14.9 million, up from $11.9 million in Q4 2023, reflecting increased clinical costs related to IMM-1-104 [7][17] - The net loss for Q4 2024 was $18.1 million, or $0.58 per share, compared to a net loss of $15.1 million, or $0.52 per share, for Q4 2023 [7][17] Leadership Changes - Dr. Igor Matushansky has been appointed as Chief Medical Officer to oversee clinical activities and development programs [4][5]
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Globenewswire· 2025-03-20 11:00
Core Viewpoint - Immuneering has appointed Dr. Igor Matushansky as Chief Medical Officer to lead clinical activities and oversee the ongoing Phase 2a study of IMM-1-104 in pancreatic cancer, with plans for a pivotal Phase 3 trial in the future [1][2] Company Overview - Immuneering is a clinical-stage oncology company focused on developing and commercializing therapies that are more effective and better tolerated for cancer patients [3] - The lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK aimed at improving tolerability and expanding indications for RAS-driven tumors, including pancreatic cancer [3] Clinical Development - The ongoing Phase 2a trial of IMM-1-104 is designed to provide first-line pancreatic cancer patients with a new treatment option that is more effective and better tolerated than current standard care [2] - The company plans to present updated data from the Phase 2a trial in Q2 2025 [1] Leadership Experience - Dr. Matushansky brings extensive oncology drug development experience, having previously served as Chief Medical Officer at Sail Biomedicines and held senior roles at Ipsen Pharmaceuticals and Hookipa Pharma [2] - His background includes overseeing the completion of NAPOLI-3, which led to the approval of NALIRIFOX for first-line pancreatic cancer [2]
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Newsfilter· 2025-02-06 12:00
- Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1 – CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced a ...
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Globenewswire· 2025-02-03 21:05
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief E ...
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Newsfilter· 2025-01-13 13:00
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Nearly $14M in net proceeds raised in January 2025 through utilization of Company's ATM - CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effecti ...
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
Newsfilter· 2025-01-07 12:00
- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1- ...
Immuneering Launches Pancreatic Cancer Advisory Board
Globenewswire· 2024-12-19 13:00
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation ...
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Globenewswire· 2024-12-17 13:00
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and ...
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
GlobeNewswire News Room· 2024-12-12 13:00
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinica ...